Business Context and Reporting Period
Heron Therapeutics, Inc. filed its Form 10-K for the fiscal year ended December 31, 2018. Heron is a commercial-stage biotechnology company developing products based on its Biochronomer drug-delivery technology for chemotherapy-induced nausea and vomiting and postoperative pain.
- Commercial products: SUSTOL, launched in 2016, and CINVANTI, launched in January 2018.
- Pipeline: HTX-011, an investigational long-acting bupivacaine/meloxicam product for postoperative pain, was under FDA Priority Review with a PDUFA goal date of April 30, 2019. HTX-034 was in formal development.
- As of February 1, 2019, Heron had 198 full-time employees and 78.2 million common shares outstanding as of December 31, 2018.
Financial Performance and Position
| Metric | FY 2018 | FY 2017 | Change |
|---|---|---|---|
| Net product sales | $77.5 million | $30.8 million | +151.8% |
| Gross profit | $50.0 million | $26.2 million | +90.7% |
| Gross margin | 64.5% | 85.1% | Down 20.6 percentage points |
| Research and development | $140.0 million | $138.6 million | +1.0% |
| General and administrative | $29.3 million | $25.6 million | +14.5% |
| Sales and marketing | $64.6 million | $56.6 million | +14.1% |
| Loss from operations | $(183.9) million | $(194.6) million | Improved $10.6 million |
| Net loss | $(178.8) million | $(197.5) million | Improved $18.6 million |
| Net loss per share | $(2.44) | $(3.65) | Improved $1.21 |
| Cash used in operations | $(191.8) million | $(170.3) million | Use increased $21.5 million |
- SUSTOL net product sales were $21.3 million under the new revenue standard, versus $30.8 million in 2017. CINVANTI generated $56.2 million in its first commercial year.
- Gross margin declined primarily because 2018 included the cost of commercial CINVANTI inventory and a $1.8 million write-off of short-dated SUSTOL inventory.
- Cash, cash equivalents and short-term investments totaled $332.4 million at year-end, including $31.8 million of cash and cash equivalents and $300.5 million of short-term investments.
- Working capital was $355.2 million, compared with $124.9 million at December 31, 2017. Accounts receivable were $64.7 million and inventory was $39.0 million.
- Heron reported an accumulated deficit of $960.7 million and no income tax provision because deferred tax assets were fully offset by a valuation allowance.
Material Changes Versus the Prior Comparable Period
- Revenue increased substantially with the launch of CINVANTI, although reported SUSTOL revenue declined. Revenue comparability was also affected by adoption of ASC Topic 606 on January 1, 2018, which changed recognition from a sell-through to a sell-in approach and increased opening accumulated deficit by $1.6 million.
- Research and development spending remained broadly stable. HTX-011-related costs increased to $81.9 million from $78.1 million, while CINVANTI- and SUSTOL-related development costs declined.
- Commercialization and infrastructure spending increased, reflected in higher sales and marketing and general and administrative expenses.
- Operating and net losses narrowed despite higher operating cash use, aided partly by $5.1 million of net other income in 2018 versus $2.9 million of net expense in 2017. The 2018 amount included $1.9 million from disgorgement of short-swing profits and higher investment income.
- Heron raised $363.1 million net from two common-stock offerings and received $18.3 million from stock-option exercises. Shares outstanding increased from 64.6 million to 78.2 million.
- The $25.0 million related-party Promissory Note was repaid in August 2018. The remaining Convertible Notes had $6.8 million of principal outstanding and a $4.6 million carrying value at year-end.
Cash Flow, Debt and Liquidity
- Operating cash burn was $191.8 million, driven in part by increases in accounts receivable and inventory associated with the product launches.
- Investing cash use was $278.6 million, primarily reflecting net purchases of short-term investments of $269.4 million and property and equipment purchases of $9.2 million.
- Financing cash inflow was $357.6 million, primarily from equity offerings, partially offset by repayment of the Promissory Note.
- Management stated that year-end cash, cash equivalents and short-term investments were sufficient to fund operations for at least one year from the filing date, based on the current operating plan.
- Contractual obligations totaled $77.4 million, including $54.4 million of purchase obligations, $17.8 million of operating lease obligations and $5.1 million of capital expenditure commitments. These amounts exclude variable future clinical-trial costs.
- The Convertible Notes bear interest at 6%, mature in 2021, are secured by substantially all assets and may be subject to holder-requested prepayment. Full conversion of principal and accrued interest as of year-end would have required issuance of approximately 8.5 million shares, or 9.8% of shares outstanding after conversion.
Guidance, Outlook, Risks and Unusual Items
- Management expected 2019 research and development expense to increase for HTX-011 and HTX-034 development, manufacturing costs and post-marketing requirements for SUSTOL and CINVANTI.
- General and administrative expense was expected to increase to support development and commercialization. Sales and marketing expense was expected to increase for ongoing SUSTOL and CINVANTI commercialization and a potential HTX-011 launch.
- HTX-011 had Fast Track, Breakthrough Therapy and Priority Review designations. The filing reported positive Phase 2b and Phase 3 results, but approval and commercial launch remained uncertain as of the filing date.
- Key commercial risks include intense competition, generic entry affecting SUSTOL, reimbursement and pricing pressure, reliance on a limited number of specialty distributors, and customer concentration. Three customers represented 99.1% of 2018 net product sales and 99.6% of year-end accounts receivable.
- Heron relies on a small number of third-party manufacturers, and certain critical materials are sourced from single suppliers. Manufacturing scale-up, supply interruptions, product quality and inventory obsolescence could materially affect results.
- The company had a history of substantial losses and negative operating cash flow and stated that it may require additional financing. Future equity financing could dilute shareholders, while debt financing could be restricted by existing Convertible Note covenants.
- No material legal proceedings or off-balance-sheet arrangements were reported. The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important Facts for Investors to Verify
- Whether CINVANTI sales growth and reimbursement access can offset declining or pressured SUSTOL sales following generic ALOXI competition.
- The FDA’s final action on HTX-011, the approved label, launch timing, manufacturing readiness and required post-approval studies.
- Quarterly product sales, gross margin and sales allowances, particularly product returns, discounts, rebates and distributor fees.
- Operating cash burn, inventory levels and accounts receivable collections relative to the company’s stated liquidity runway.
- Future financing needs, the terms and potential conversion or prepayment of the Convertible Notes, and dilution from outstanding options, warrants and convertible shares.
- Exposure to customer concentration, third-party manufacturing and single-source supply risks.